Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Erythropoietin can obviate the need for repeated heart valve replacement in high-risk patients with severe mechanical hemolytic anemia: Case reports and literature review
Autore:
Shapira, Y; Bairey, O; Vatury, M; Magen-Nativ, H; Prokocimer, M; Sagie, A;
Indirizzi:
Rabin Med Ctr, Dept Cardiol, Valvular Clin, IL-49100 Petah Tiqwa, Israel Rabin Med Ctr Petah Tiqwa Israel IL-49100 , IL-49100 Petah Tiqwa, Israel Rabin Med Ctr, Dan Sheingarten Echocardiog Unit, IL-49100 Petah Tiqwa, Israel Rabin Med Ctr Petah Tiqwa Israel IL-49100 , IL-49100 Petah Tiqwa, Israel Rabin Med Ctr, Inst Hematol, IL-49100 Petah Tiqwa, Israel Rabin Med Ctr Petah Tiqwa Israel IL-49100 , IL-49100 Petah Tiqwa, Israel
Titolo Testata:
JOURNAL OF HEART VALVE DISEASE
fascicolo: 4, volume: 10, anno: 2001,
pagine: 431 - 435
SICI:
0966-8519(200107)10:4<431:ECOTNF>2.0.ZU;2-U
Fonte:
ISI
Lingua:
ENG
Soggetto:
RECOMBINANT-HUMAN-ERYTHROPOIETIN; CARDIAC HEMOLYSIS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
10
Recensione:
Indirizzi per estratti:
Indirizzo: Shapira, Y Rabin Med Ctr, Dept Cardiol, Ecocardiog & Valvular Clin, Belinson Campus, IL-49100 Petah Tiqwa, Israel Rabin Med Ctr Belinson Campus PetahTiqwa Israel IL-49100 rael
Citazione:
Y. Shapira et al., "Erythropoietin can obviate the need for repeated heart valve replacement in high-risk patients with severe mechanical hemolytic anemia: Case reports and literature review", J HEART V D, 10(4), 2001, pp. 431-435

Abstract

Background and aim of the study: Brisk hemolysis due to perivalvular leak is usually an indication for valve re-replacement. Repeated surgery after multiple previous valve operations is associated with high mortality, morbidity and failure rates. The present study evaluated the role of erythropoietin (EPO) administration in deferring or obviating the need for repeated surgery. Methods: Three patients (two men, one woman; age range 62-76 years) with two mechanical valves each and two to four previous heart valve operations, who suffered from severe mechanical hemolytic anemia, were given subcutaneous EPO for 15-17 months. Results: A marked reduction in red blood cell consumption was achieved with a weekly EPO dose of 18,000 U in two patients, both of whom also had mildor moderate kidney malfunction. A third patient with normal renal functionand extreme hemolysis showed a transient, partial response to 30,000 U of EPO per week, and eventually needed a fifth operation. Conclusion: EPO may defer or even obviate the need for repeated valve surgery in patients with severe hemolysis due to perivalvular leak, especially those with inadequate EPO response, such as those with renal malfunction.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/09/20 alle ore 00:20:39